Since these initial clinical trials were conducted exclusively in patients with type II diabetes, it remained unclear whether the nephroprotective effects due to SGLT2 inhibition could be translated to non-diabetic chronic kidney disease (CKD). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.